Dr. Ranjan Dahal, MD

Dr. Dahal practices at Longview Regional Medical Center in Longview, Texas, part of Community Health Systems.

Dr. Dahal's NPI, 1194070482, was assigned on July 23, 2012. Dr. Dahal graduated from Tribhuvan University Inst of Medicine in 2010. Dr. Dahal holds Texas license S9285.

Dr. Dahal's primary practice is Longview Regional Medical Center, at 2901 N Fourth St, Longview, TX 75605 in Gregg County. The practice phone is (903) 758-1818.

Dr. Dahal's primary practice is Longview Regional Medical Center in Longview, Texas, part of Community Health Systems. Dr. Dahal is also affiliated with CHRISTUS Good Shepherd Medical Center - Longview. The medical group on file is Regional Clinics. Dmand AI also links Dr. Dahal to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dahal practices, 3 sites in all. Vendor and product names are available with a free account.

Interventional cardiology is Dr. Dahal's primary specialty in the NPI Registry, under taxonomy code 207RI0011X. Dr. Dahal is board certified in cardiovascular disease by the American Board of Internal Medicine. Dmand AI has Dr. Dahal's licenses on file in 3 states: Texas, New Jersey and Maryland.

Dmand AI lists angioplasty among the conditions Dr. Dahal treats.

CMS data shows 2,756 Medicare services from Dr. Dahal across 23 procedure codes in 2024, for 858 Medicare patients. Medicare paid $179,383 for them.

CMS counts 858 Medicare patients who saw Dr. Dahal in 2024. The largest group is 65 to 74, with 359 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.67, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dahal's median patient age at 75, with 49% women.

In 2024, Dr. Dahal wrote 2,867 Medicare Part D claims for 462 patients. 84% of them were for generic drugs. CMS names the drug for 2,701 of them, across 41 drugs with 11 or more claims each, at $438,478 in total drug cost. In 2023, CMS named 303 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Dahal for performance year 2024, reported through an alternative payment model (APM). Dr. Dahal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 57 procedures of coronary angioplasty and stenting by Dr. Dahal, more than 87% of the clinicians it reports for that procedure.

Leg revascularization (restoring blood flow): 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 9 papers to Dr. Dahal, published from 2018 to 2022. The most frequent topics are Heart Failure and Nepal. Dr. Dahal has published most often in Cardiovasc Hematol Disord Drug Targets. Dr. Dahal's most frequent co-authors are Sangita Bista, Debabrata P. Mukherjee, MD and Moeen Abedin, MD.

CMS Open Payments shows 187 general payments to Dr. Dahal from 28 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 92% of the total. Boston Scientific Corporation paid the most, $1,387.

Dr. Dahal graduated from Tribhuvan University Inst of Medicine in 2010. Dr. Dahal is a member of ACC and SCAI.

Dr. Dahal is in network with 15 carriers, including Aetna, United Healthcare and Elevance. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.